Proteomic Analysis Shows Constitutive Secretion of MIF and p53-associated Activity of COX-2−/− Lung Fibroblasts
暂无分享,去创建一个
Roderick V. Jensen | Mandar Dave | Abul Bashar Mir Md Khademul Islam | Agueda Rostagno | Jorge Ghiso | Ashok R. Amin | R. Jensen | J. Ghiso | A. Rostagno | A. B. Islam | M. Dave | A. Amin
[1] S. Abramson,et al. Activation of diverse eicosanoid pathways in osteoarthritic cartilage: a lipidomic and genomic analysis. , 2012, Bulletin of the NYU hospital for joint diseases.
[2] R. Bucala,et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. , 1999, Arthritis and rheumatism.
[3] L. Leng,et al. Autoimmune diseases: MIF as a therapeutic target , 2010, Expert opinion on therapeutic targets.
[4] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[5] D. Townsend,et al. Glutathione S-transferase polymorphisms: cancer incidence and therapy , 2006, Oncogene.
[6] A. Levine,et al. The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.
[7] B. Wong,et al. Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs. , 2004, Carcinogenesis.
[8] P. Hainaut,et al. Cross‐talks between cyclooxygenase‐2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis , 2007, International journal of cancer.
[9] X. Bian,et al. MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis , 2015, Oncotarget.
[10] S. Kulp,et al. 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells , 2004, Cancer Research.
[11] G. Fingerle-Rowson,et al. MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models , 2007, Cell Division.
[12] John David,et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] D. Templeton,et al. Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment , 2012, The Journal of Immunology.
[14] Roderick V. Jensen,et al. Genomic, Lipidomic and Metabolomic Analysis of Cyclooxygenase-null Cells: Eicosanoid Storm, Cross Talk, and Compensation by COX-1 , 2016, Genom. Proteom. Bioinform..
[15] G. Boulianne,et al. Diverse structures, functions and uses of FK506 binding proteins. , 2017, Cellular signalling.
[16] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[17] J. Bernhagen,et al. Macrophage migration inhibitory factor (MIF): a promising biomarker. , 2010, Drug news & perspectives.
[18] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[19] Hyun-A Seong,et al. Critical Role of Cysteine Residue 81 of Macrophage Migration Inhibitory Factor (MIF) in MIF-induced Inhibition of p53 Activity* , 2008, Journal of Biological Chemistry.
[20] R. Atkins,et al. Migration inhibitory factor expression in experimentally induced endotoxemia. , 1997, The American journal of pathology.
[21] R. Bucala,et al. Role of macrophage migration inhibitory factor in age-related lung disease. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[22] Zhen Xiao,et al. Proteomic Profiling Identifies Cyclooxygenase-2-Independent Global Proteomic Changes by Celecoxib in Colorectal Cancer Cells , 2006, Cancer Epidemiology Biomarkers & Prevention.
[23] C. Chizzolini,et al. Prostaglandin E2: igniting the fire , 2009, Immunology and cell biology.
[24] Andreas Prlic,et al. Ensembl 2007 , 2006, Nucleic Acids Res..
[25] Michael R. Elliott,et al. RahU: an inducible and functionally pleiotropic protein in Pseudomonas aeruginosa modulates innate immunity and inflammation in host cells. , 2011, Cellular immunology.
[26] Carol Prives,et al. Mutant p53: one name, many proteins. , 2012, Genes & development.
[27] T. Hla,et al. Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest , 1999, The Journal of Biological Chemistry.
[28] S. Donnelly,et al. Inflammation and cancer: macrophage migration inhibitory factor (MIF)—the potential missing link , 2010, QJM : monthly journal of the Association of Physicians.
[29] J. Nishihira,et al. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[30] C. Prives,et al. Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.
[31] S. Laulederkind,et al. Compensatory Prostaglandin E2 Biosynthesis in Cyclooxygenase 1 or 2 Null Cells , 1998, The Journal of experimental medicine.
[32] M. Rizzo. Cyclooxygenase-2 in oncogenesis. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[33] Ron D. Appel,et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..
[34] Yuhei Yamamoto,et al. Decreased prostaglandin E2 production by inflammatory cytokine and lower expression of EP2 receptor result in increased collagen synthesis in keloid fibroblasts. , 2006, The Journal of investigative dermatology.
[35] M. Teixeira,et al. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] K. Meyer-Siegler. COX-2 Specific Inhibitor, NS-398, Increases Macrophage Migration Inhibitory Factor Expression and Induces Neuroendocrine Differentiation in C4-2b Prostate Cancer Cells , 2001, Molecular medicine.
[37] R. DuBois,et al. Eicosanoids and cancer , 2010, Nature Reviews Cancer.
[38] A. Minami,et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). , 2004, Cytokine.
[39] R. Wierenga,et al. Triosephosphate isomerase: a highly evolved biocatalyst , 2010, Cellular and Molecular Life Sciences.
[40] N. Altorki,et al. Inhibition of Cyclooxygenase-2 Gene Expression by p53* , 1999, The Journal of Biological Chemistry.
[41] R. Dodel,et al. Role of MIF in Inflammation and Tumorigenesis , 2008, Oncology.
[42] Lawrence J. Marnett,et al. Cyclooxygenases: structural and functional insights Research on COX structure and function in the authors' laboratory is supported by grants from the National Institutes of Health (CA-89450 and GM-15431). Published, JLR Papers in Press, October 23, 2008. , 2009, Journal of Lipid Research.
[43] G. Semenza,et al. Macrophage Migration Inhibitory Factor Activates Hypoxia-Inducible Factor in a p53-Dependent Manner , 2008, PloS one.
[44] R. Maizels,et al. The secretome of the filarial parasite, Brugia malayi: proteomic profile of adult excretory-secretory products. , 2008, Molecular and biochemical parasitology.
[45] S. Kim,et al. Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53. , 2009, Biochimica et biophysica acta.
[46] Yoshihiro Yamanishi,et al. KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..
[47] P. Ongusaha,et al. p53‐mediated induction of Cox‐2 counteracts p53‐ or genotoxic stress‐induced apoptosis , 2002, The EMBO journal.
[48] D. Hicklin,et al. Monoclonal antibody strategies to block angiogenesis. , 2001, Drug discovery today.
[49] O. Lesur,et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF) , 2011, Proceedings of the National Academy of Sciences.
[50] H. Kolb,et al. Production and release of macrophage migration inhibitory factor from human adipocytes. , 2005, Endocrinology.
[51] D. Townsend,et al. The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.
[52] Amos Bairoch,et al. ScanProsite: a reference implementation of a PROSITE scanning tool. , 2002, Applied bioinformatics.
[53] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[54] S. Saussez,et al. Macrophage migration inhibitory factor involvement in breast cancer (Review) , 2015, International journal of oncology.
[55] D. Meek. Regulation of the p53 response and its relationship to cancer. , 2015, The Biochemical journal.
[56] Nuria Lopez-Bigas,et al. IntOGen: integration and data mining of multidimensional oncogenomic data , 2010, Nature Methods.
[57] Nuria Lopez-Bigas,et al. Gitools: Analysis and Visualisation of Genomic Data Using Interactive Heat-Maps , 2011, PloS one.
[58] A. Javeed,et al. Macrophage-migration inhibitory factor: role in inflammatory diseases and graft rejection , 2008, Inflammation Research.
[59] S. Abramson,et al. Regulation of cytosolic COX-2 and prostaglandin E2 production by nitric oxide in activated murine macrophages. , 1999, Journal of immunology.
[60] S. Abramson,et al. Nitric Oxide Synthase/COX Cross-Talk: Nitric Oxide Activates COX-1 But Inhibits COX-2-Derived Prostaglandin Production1 , 2000, The Journal of Immunology.
[61] W. Kamps,et al. Evidence Based Selection of Housekeeping Genes , 2007, PloS one.
[62] Heather R. Roberts,et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. , 2009, Carcinogenesis.